Sweden-based biopharmaceutical company OxThera has randomised the first patient in a Phase III trial, EPHEX, designed to evaluate the safety and efficacy of Oxabact in treating patients with primary hyperoxaluria (PH).

PH is a rare autosomal recessive disorder that causes significantly elevated levels of endogenous oxalate, causing kidney deterioration and a gradual calcification of soft tissues.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

If not treated, the disease can lead to kidney failure and premature death.

“With Oxabact, we are attempting to reduce the systemic oxalate crystal burden and hope to demonstrate that chronic treatment with Oxabact can preserve kidney function for these patients.”

The EPHEX trial is a randomised, placebo-controlled, 52-week study that aims to demonstrate Oxabact’s ability to halt or delay the disease progression and preserve kidney function.

OxThera CEO Matthew Gantz said: “With Oxabact, we are attempting to reduce the systemic oxalate crystal burden and hope to demonstrate that chronic treatment with Oxabact can preserve kidney function for these patients.”

Oxabact is an oral solution composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This commensal bacteria is capable of promoting the enteric elimination of oxalate, thereby minimising the oxalate burden in the kidneys.

Last November, OxThera received two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan for the treatment of hyperoxaluria.

The US patents US8900575 and US8940295 cover pharmaceutical compositions of oxalate decarboxylase.

The European patents EP2449098 cover pharmaceutical compositions of oxalate decarboxylase, while EP1771201 and EP1965816 cover pharmaceutical compositions of Oxalobacter formigenes.